This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
by Zacks Equity Research
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
CDTXPositive Net Change ALLONegative Net Change AKRONegative Net Change CMMBNegative Net Change
biotechs
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
by Kinjel Shah
Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.
NVSNegative Net Change BIIBNegative Net Change SUPNNegative Net Change PTCTPositive Net Change
biotechs
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
by Zacks Equity Research
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
OVIDNegative Net Change ALLONegative Net Change AKRONegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
by Ahan Chakraborty
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change AKRONegative Net Change
biotechnology biotechs medical pharmaceuticals
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
by Ahan Chakraborty
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
by Ekta Bagri
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
by Zacks Equity Research
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change
biotechnology biotechs medical
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering
by Zacks Equity Research
Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.
RDYPositive Net Change ESPRPositive Net Change SDZNYNegative Net Change
biotechs medical
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
by Zacks Equity Research
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
JNJNegative Net Change BAYRYNegative Net Change FOLDPositive Net Change SPRONegative Net Change
biotechnology biotechs medical pharmaceuticals
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
by Zacks Equity Research
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
KALANegative Net Change ALLONegative Net Change AKRONegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
by Zacks Equity Research
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
AZNNegative Net Change ALLONegative Net Change AKRONegative Net Change CMMBNegative Net Change
biotechs
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
by Zacks Equity Research
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
BIIBNegative Net Change BMYNegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
by Zacks Equity Research
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
RHHBYPositive Net Change JNJNegative Net Change HALONegative Net Change
biotechs
Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
by Zacks Equity Research
AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.
PFENegative Net Change AMGNNegative Net Change GDRXNegative Net Change
biotechs medical pharmaceuticals
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
by Zacks Equity Research
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
NVONegative Net Change FOLDPositive Net Change AVDLNegative Net Change SKYEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
by Ahan Chakraborty
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
by Zacks Equity Research
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
GSKPositive Net Change MRKNegative Net Change GILDPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
by Zacks Equity Research
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
AZNNegative Net Change PFENegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
by Zacks Equity Research
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
RHHBYPositive Net Change JAZZNegative Net Change ETNBNegative Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
by Sundeep Ganoria
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
AZNNegative Net Change PFENegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
by Zacks Equity Research
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
CRMDNegative Net Change MRUSNegative Net Change KNSANegative Net Change GMABNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Can Novo Nordisk's Restructuring Program Drive its Return to Growth?
by Ahan Chakraborty
NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.
BMYNegative Net Change NVONegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?
by Sundeep Ganoria
Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.
PFENegative Net Change MRKNegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs medical pharmaceuticals
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
by Kanishka Das
Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
SNYNegative Net Change TEVANegative Net Change FOLDPositive Net Change
biotechs
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
by Zacks Equity Research
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
BMYNegative Net Change BAYRYNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals